A Canadian company investigating an experimental treatment for Ebola may be months away from making new drug supplies, offering no guarantee on Wednesday evening that its unapproved treatment would reach patients.
“The regulatory framework to support its use in Africa has not yet been established,” Tekmira Chief Executive Officer Mark Murray told analysts on an earnings call. “There can be no assurance that an appropriate framework” will be developed.
Vancouver-based Tekmira is one of several companies trying to develop treatments for the deadly virus that has killed more than 1,000 people in West Africa this year, mostly in Guinea, Liberia, and Sierra Leone.
Help employers find you! Check out all the jobs and post your resume.
